AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 69441: 1,3-Isobenzofurandione, 4,5,6,7-tetraiodo-

Chemical compound data from PubChem database. IUPAC Name: 4,5,6,7-tetraiodo-2-benzofuran-1,3-dione. Molecular Formula: C8I4O3. Molecular Weight: 651.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Care Licensing Study, 2005

The purpose of the 2005 Child Care Licensing Study was to report two aspects of child care licensing from 2005 for all 50 states and the District of Columbia: (1) state child care licensing programs and policies, and (2) child care center licensing regulations. 

To collect information on states' licensing policies, including staffing, monitoring, and enforcement of licensing regulations, the National Association for Regulatory Administration (NARA) disseminated the 2005 NARA Child Care Licensing Program Survey to all state child care licensing agencies in February 2005. Responses were received from all states. The survey focuses on the processes and policies in each state related to staffing for the licensing program, monitoring facilities, and enforcement of licensing regulations. 

<b>Units of Response: </b>State  

<b>Type of Data: </b>Survey 

<b>Tribal Data: </b>No 

<b>Periodicity: </b>Irregular 

<b>Demographic Indicators: </b>Not Applicable

<b>SORN: </b> https://www.federalregister.gov/documents/2022/01/24/2022-01066/privacy-act-of-1974-system-of-records 

<b>Data Use Agreement: </b>Unavailable 

<b>Data Use Agreement Location: </b> Not Applicable 

<b>Granularity: </b>State 

<b>Spatial: </b>United States 

<b>Geocoding: </b>Unavailable
Patent AT-E401437-T1: [Translated] HELTED THERMOPLASTIC POLYPROPYLENE FIBERS, PRODUCTION PROCESS AND NON-WOVEN MATERIALS PRODUCED BY THERMALLY SOLIDIFICATION OF THESE FIBERS

The polypropylene-based thermoplastic fibers are uniform in cross-section, not having any degraded surface skin, and they are heat-weldable at a pressure at a temperature which is lower than the melting temperature, by virtue of internal heating due to the effect of said pressure. They are made of a first constituent with high crystallinity and at least one second constituent, compatible with the first constituent, and of crystallinity that is lower than that of the first constituent. They have a quantity of primary oxidation inhibitor lying in the range 350 ppm to 1000 ppm. Such fibers are made by spinning under conditions that avoid molecular degradation by thermal oxidation at the periphery of the fibers, in particular with cooling that is rapid immediately on leaving the extrusion head. The non-woven fabric obtained by heat-bonding such fibers is characterized by weld points that are in the form of a polymer laminate that is uniform and transparent.
Indiana 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: The University of Oklahoma Health Sciences Center

Location:

Oklahoma City, Oklahoma

Home Visiting Program Selected:

SafeCare

Home Visiting Target Population:

Families with at least one child age 5 years or younger and at least one of the following risk factors: parental substance abuse, mental health issues, and/or intimate partner violence.

Project Overview:
The University of Oklahoma Health Sciences Center will build on their experience developing, implementing, evaluating, and expanding evidence-based home visiting programs serving high-risk populations. Oklahoma will evaluate SafeCare® augmented to address risks of intimate partner violence, substance abuse, and depression with Motivational Interviewing, safety planning, and problem solving (SafeCare+). Through this grant, Oklahoma will expand the SafeCare+ model by selecting an evidence-based augmentation to promote nonviolent behavior and conflict resolution skills, and implementing adaptations for receptivity and cultural congruency for the Oklahoma Latino community. Oklahoma will conduct a randomized trial comparing SafeCare+ to one or more other home-based service approaches offered at the Latino Community Development Agency. The violence prevention augmentation will also be evaluated in an ongoing randomized trial. To focus on systems change, the Sustaining Prevention Programs committee will examine private, municipal, state, and federal funding streams and cost benefits data to plan for the continuation and expansion of evidence-based high risk child maltreatment prevention in Oklahoma.

Metadata-only record linking to the original dataset. Open original dataset below.
NNDSS - TABLE 1GG. Smallpox to Streptococcal toxic shock syndrome

NNDSS - TABLE 1GG. Smallpox to Streptococcal toxic shock syndrome – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Linkage analysis of HLA and candidate genes for celiac disease in a North American family-based study

Background
          Celiac disease has a strong genetic association with HLA. However, this association only explains approximately half of the sibling risk for celiac disease. Therefore, other genes must be involved in susceptibility to celiac disease. We tested for linkage to genes or loci that could play a role in pathogenesis of celiac disease.
        
        
          Methods
          DNA samples, from members of 62 families with a minimum of two cases of celiac disease, were genotyped at HLA and at 13 candidate gene regions, including CD4, CTLA4, four T-cell receptor regions, and 7 insulin-dependent diabetes regions. Two-point and multipoint heterogeneity LOD (HLOD) scores were examined.
        
        
          Results
          The highest two-point and multipoint HLOD scores were obtained in the HLA region, with a two-point HLOD of 3.1 and a multipoint HLOD of 5.0. For the candidate genes, we found no evidence for linkage.
        
        
          Conclusions
          Our significant evidence of linkage to HLA replicates the known linkage and association of HLA with CD. In our families, likely candidate genes did not explain the susceptibility to celiac disease.
Patent AT-E400589-T1: [Translated] FLUORPOLYMERS AND MEMBRANES MADE THEREOF, IN PARTICULAR FOR FUEL CELLS, AND METHOD FOR SYNTHESIS OF SUCH POLYMERS

Fluorinated polymer (I), comprising repetitive units of formula (-CXY1-CZ(CH 2-O-Ar1-Q-G)-), is new. Fluorinated polymer (I), comprising repetitive units of formula (-CXY1-CZ(CH 2-O-Ar1-Q-G)-), is new. X, Y : H or F; Z : F or perfluoroalkyl; Ar1 : carbonated aromatic cycle (optionally substituted); Q : a bond, (CF 2) n (where, 1=n=10) or C 2F 4OC 2F 4; G : SO 2R 1, P(=O)(OR 2) 2 or CO 2H; R 1OH, F or Cl; and R 2H or alkyl (optionally substituted). Independent claims are also included for: (1) the preparation of (I); (2) a membrane (V) comprising (I); and (3) a fuel cell device comprising (V).
Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years, United States, Data Source: Centers for Medicare & Medicaid Services Chronic Conditions Warehouse

Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged 65 years

• Estimated COVID-19 vaccination coverage among Medicare fee-for-service beneficiaries >65 years is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS). 

• Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html
Colorado (CO)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Colorado overall and for substate regions within Colorado. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Compound 527499: D-Fructose, pentakis-TMS ether

Chemical compound data from PubChem database. IUPAC Name: (3R,4S,5S)-1,3,4,5,6-pentakis(trimethylsilyloxy)hexan-2-one. Molecular Formula: C21H52O6Si5. Molecular Weight: 541.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study

Background
          The gene encoding apolipoprotein E (APOE) has been proposed as a candidate gene for vascular complications in Type I diabetes. This study aimed to investigate the influence of three-allelic variations in the APOE gene for the development of diabetic retinopathy and nephropathy.
        
        
          Results
          Neither APOE alleles frequencies or APOE genotypes frequencies differed between Type I diabetic groups either with or without nephropathy. Similar results were found for patients with and without diabetic retinopathy.
        
        
          Conclusions
          APOE gene polymorphism does not determine genetic susceptibility for the development of diabetic retinopathy in Type I diabetes patients. Association between APOE gene polymorphism and diabetic nephropathy may be weak or moderate, but not strong.
Oregon's Monthly Reportable Disease Data

Preliminary demographic data for cases of selected reportable diseases in Oregon. Oregon physicians, other health care providers and laboratorians are required to report diagnoses of certain diseases and conditions to local health departments (OAR Chapter 333, Division 18). People who were diagnosed with a reportable disease or condition are referred to as 'cases.' Reporting enables appropriate public health follow-up to prevent spread and provides a better understanding of disease patterns in Oregon.

These data expand upon Oregon's Weekly Reportable Disease Data. Demographic stratifications more granular than statewide with fewer than six cases are masked; annual summaries present demographic data over longer timeframes.
Compound 525222: Methyl undecyl terephthalate

Chemical compound data from PubChem database. IUPAC Name: 1-O-methyl 4-O-undecyl benzene-1,4-dicarboxylate. Molecular Formula: C20H30O4. Molecular Weight: 334.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Emergency Department Visits Involving Methamphetamine: 2007 to 2011

This short report uses data on drug-related emergency department (ED) visits from the Drug Abuse Warning Network to examine the trends in ED visits involving methamphetamine from 2007 to 2011.  In addition to the trends for total methamphetamine-related visits, it also shows trends by gender and by age group; the age distribution of patients; the drugs most commonly combined with methamphetamine; and the outcome of the ED visits.
V-safe Registration

Users of the V-safe data are required to adhere to the following standards for the analysis and reporting of research data. All research results must be presented and/or published in a manner that protects the confidentiality of participants. V-safe data will not be presented and/or published in any way in which an individual can be identified. Therefore, users will:
<ol>
<li>Not attempt to link or permit others to link the data with individually identified records in another database.</li>
<li>Not attempt to learn the identity of any participant in the data and will not deliberately combine these data with other CDC or non-CDC data for the purpose of matching records to identify individuals. If you should inadvertently discover the identity of any participant, you will ensure the identity of any participant is kept confidential, and will not be used in any publications and/or presentations.</li>
<li>Not imply or state, either in written or oral form, that interpretations based on analysis of the data reflect official CDC policies or positions.</li>
<li>Understand that sub-national analyses are not appropriate for this national sample and will not be conducted. </li>
<li>Understand that V-safe is a voluntary self-enrollment program requiring smartphone access; therefore, information from V-safe might not be representative or generalizable to the US population.</li></ol>
By clicking on the weblink below to download and use these V-safe data, you signify your agreement to comply with the above-stated terms.

V-safe is a voluntary U.S. active safety surveillance system established by CDC to characterize local and systemic side effects of new vaccines administered after U.S. authorization or licensure. V-safe participants are not a random sample of all vaccinated persons in the United States and data might not be generalizable to the full U.S. vaccinated population. Participants may have been more likely to complete surveys if experiencing symptoms post-vaccination. All V-safe measures are self-reported, therefore there may be some misclassification of outcomes, vaccine-related information, or demographics.

Occasional system outages and attrition over time may contribute to incomplete reporting. 

V-safe Registration public data includes de-identified demographic data for all participants that registered to V-safe from 10/20/2023 to 3/23/2025.  Corresponding protocol data (RSV for Adults, RSV for Pregnant Women, and COVID-19) can be downloaded at data.cdc.gov.  Please review the V-safe data user agreement before analyzing any V-safe data.
Racial/Ethnic Differences in Mental Health Service Use among Adults

This chartbook uses combined 2008 to 2012 data from the National Survey on Drug Use and Health (NSDUH) to presentnationally representative estimates of mental health service utilization among adults aged 18 or older within different racial/ethnicgroups in the United States. Data on racial/ethnic differences in mental health service utilization also are examined inthe context of other characteristics, such as age, gender, marital status, employment status, poverty status, insurance status, overall health, substance use disorder status, and education.
Program Instruction (PI-19-01)

This Program Instruction (PI) provides guidance to state, territorial and tribal title IV-E agencies on the actions required to apply for title IV-B, subpart 2 funding to support the development, enhancement or evaluation of kinship navigator programs. These are federal fiscal year (FY) 2019 funds, provided as part of P.L.115-245, the Department of Defense and Labor, Health and Human Services, and Education Appropriations Act of 2019, enacted September 28, 2018.

Metadata-only record linking to the original dataset. Open original dataset below.
NNDSS - Table II. Ehrlichiosis and Anaplasmosis

NNDSS - Table II. Ehrlichiosis and Anaplasmosis - 2017.  In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. 

Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
 C.N.M.I.: Commonwealth of Northern Mariana Islands. 

 U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. 

 *Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. 

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Please refer to the MMWR publication for weekly updates to the footnote for this condition.
Program Instruction (PI-05-04)

This Program Instruction (PI) provides instruction to states on the June 30, 2005 submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Social Security Act (the Act), the Child Abuse Prevention and Treatment Act (CAPTA), and the Chafee Foster Care Independence Program (CFCIP), including the Education and Training Vouchers (ETV) program; and the CFS-101, Parts I and II, Annual Budget Request and Annual Summary of Child and Family Services.

Metadata-only record linking to the original dataset. Open original dataset below.
Child Care Market Rate Survey Project: Mail Survey of Oregon Facilities, 2006

States are required by the CCDF Final Rule to ensure that families receiving child care assistance have equal access to comparable care purchased by private-paying parents. A market rate survey (MRS) is a tool States use to achieve this program objective. Some States conduct surveys to collect the child care market rate and others use administrative data, such as data collected by child care resource and referral (CCR&R) and State licensing agencies, to analyze the market rate for child care.

This survey was one strategy used to collect child care market price data. Comparing findings garnered from different methods allows one to evaluate whether different data collection methods produce different price findings (convergent validity) and how well these data collection methods represent the child care market (criterion-related validity). These data can also be used to explore several validity issues of concern with market price studies.

<b>Units of Response: </b>Program

<b>Type of Data: </b>Survey

<b>Tribal Data: </b>No

<b>Periodicity: </b>One-time

<b>Demographic Indicators: </b>Not Applicable

<b>SORN: </b>Not Applicable

<b>Data Use Agreement: </b>Yes

<b>Data Use Agreement Location: </b>https://www.icpsr.umich.edu/rpxlogin

<b>Granularity: </b>Childcare Providers;Individual;Program;Region

<b>Spatial: </b>United States

<b>Geocoding: </b>Unavailable
Compound 527297: Propanoic acid, 2-methyl, 2-iodoethyl ester

Chemical compound data from PubChem database. IUPAC Name: 2-iodoethyl 2-methylpropanoate. Molecular Formula: C6H11IO2. Molecular Weight: 242.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526207: 2-(1-Methylpropyl)-4-tert-butylphenol

Chemical compound data from PubChem database. IUPAC Name: 2-butan-2-yl-4-tert-butylphenol. Molecular Formula: C14H22O. Molecular Weight: 206.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.